These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23003008)

  • 1. Imidazoline derivatives: a patent review (2006--present).
    Guan X; Hu Y
    Expert Opin Ther Pat; 2012 Nov; 22(11):1353-65. PubMed ID: 23003008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and biological evaluation of imidazoline derivatives as p53-MDM2 binding inhibitors.
    Hu C; Li X; Wang W; Zhang L; Tao L; Dong X; Sheng R; Yang B; Hu Y
    Bioorg Med Chem; 2011 Sep; 19(18):5454-61. PubMed ID: 21855354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imidazoline scaffold in medicinal chemistry: a patent review (2012-2015).
    Sączewski F; Kornicka A; Balewski Ł
    Expert Opin Ther Pat; 2016 Sep; 26(9):1031-48. PubMed ID: 27382975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2,4,5-Tris(alkoxyaryl)imidazoline derivatives as potent scaffold for novel p53-MDM2 interaction inhibitors: Design, synthesis, and biological evaluation.
    Bazanov DR; Pervushin NV; Savitskaya VY; Anikina LV; Proskurnina MV; Lozinskaya NA; Kopeina GS
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2364-2368. PubMed ID: 31196710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patented inhibitors of p53-Mdm2 interaction (2006 - 2008).
    Weber L
    Expert Opin Ther Pat; 2010 Feb; 20(2):179-91. PubMed ID: 20100001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53-Mdm2 inhibitors: patent review (2009 - 2010).
    Kamal A; Mohammed AA; Shaik TB
    Expert Opin Ther Pat; 2012 Feb; 22(2):95-105. PubMed ID: 22316395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of 1-arylpyrrolidone derivatives as potent p53-MDM2 inhibitors based on molecule fusing strategy.
    Li J; Wu Y; Guo Z; Zhuang C; Yao J; Dong G; Yu Z; Min X; Wang S; Liu Y; Wu S; Zhu S; Sheng C; Miao Z; Zhang W
    Bioorg Med Chem Lett; 2014 Jun; 24(12):2648-50. PubMed ID: 24813735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and CoMFA studies of N1-amino acid substituted 2,4,5-triphenyl imidazoline derivatives as p53-MDM2 binding inhibitors.
    Hu C; Dou X; Wu Y; Zhang L; Hu Y
    Bioorg Med Chem; 2012 Feb; 20(4):1417-24. PubMed ID: 22273545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simulation of MDM2 N-terminal domain conformational lability in the presence of imidazoline based inhibitors of MDM2-p53 protein-protein interaction.
    Gureev M; Novikova D; Grigoreva T; Vorona S; Garabadzhiu A; Tribulovich V
    J Comput Aided Mol Des; 2020 Jan; 34(1):55-70. PubMed ID: 31781989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent development on naphthoquinone derivatives and their therapeutic applications as anticancer agents.
    Tandon VK; Kumar S
    Expert Opin Ther Pat; 2013 Sep; 23(9):1087-108. PubMed ID: 23651032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of the p53/hdm2 protein-protein interaction-path to the clinic.
    Carry JC; Garcia-Echeverria C
    Bioorg Med Chem Lett; 2013 May; 23(9):2480-5. PubMed ID: 23541651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011-present).
    Zak K; Pecak A; Rys B; Wladyka B; Dömling A; Weber L; Holak TA; Dubin G
    Expert Opin Ther Pat; 2013 Apr; 23(4):425-48. PubMed ID: 23374098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quinazoline derivatives as potential anticancer agents: a patent review (2007 - 2010).
    Marzaro G; Guiotto A; Chilin A
    Expert Opin Ther Pat; 2012 Mar; 22(3):223-52. PubMed ID: 22404097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A therapeutic patent overview of MDM2/X-targeted therapies (2014-2018).
    Skalniak L; Surmiak E; Holak TA
    Expert Opin Ther Pat; 2019 Mar; 29(3):151-170. PubMed ID: 30822185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy.
    Zhang Z; Ding Q; Liu JJ; Zhang J; Jiang N; Chu XJ; Bartkovitz D; Luk KC; Janson C; Tovar C; Filipovic ZM; Higgins B; Glenn K; Packman K; Vassilev LT; Graves B
    Bioorg Med Chem; 2014 Aug; 22(15):4001-9. PubMed ID: 24997575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical development of p53-reactivating drugs in sarcomas - charting future therapeutic approaches and understanding the clinical molecular toxicology of Nutlins.
    Biswas S; Killick E; Jochemsen AG; Lunec J
    Expert Opin Investig Drugs; 2014 May; 23(5):629-45. PubMed ID: 24579771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
    Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
    Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear factor-kappa B inhibitors; a patent review (2006-2010).
    Kwak JH; Jung JK; Lee H
    Expert Opin Ther Pat; 2011 Dec; 21(12):1897-910. PubMed ID: 22098320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
    Zhuang C; Miao Z; Zhu L; Dong G; Guo Z; Wang S; Zhang Y; Wu Y; Yao J; Sheng C; Zhang W
    J Med Chem; 2012 Nov; 55(22):9630-42. PubMed ID: 23046248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural-activity relationship study of highly-functionalized imidazolines as potent inhibitors of nuclear transcription factor-kappaB mediated IL-6 production.
    Kahlon DK; Lansdell TA; Fisk JS; Tepe JJ
    Bioorg Med Chem; 2009 Apr; 17(8):3093-103. PubMed ID: 19328000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.